Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB26FR1PP
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $52,458
Award facts
- Contract value 100% obligated
- $52,457.82 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the pharmaceutical and healthcare solutions provider headquartered in Conshohocken, Pennsylvania, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract, valued at $52,457.82, was awarded on October 23, 2025, with an ultimate completion date of October 24, 2025, and is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at the contractor's Conshohocken facility. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vehicle designated SPE2DX and running through December 2026, which serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that supplies a broad range of pharmaceutical products and medical supplies to military and veteran healthcare systems. The company's extensive contract portfolio with the DLA demonstrates its capability to meet federal procurement requirements through open competition, with consistent awards involving delivery orders and firm fixed pricing across multiple therapeutic domains. Dupixent is a specialty pharmaceutical product used for treating conditions such as atopic dermatitis and eosinophilic asthma, aligning with the contractor's specialization in brand-name and generic medications that support Defense Health Agency and other government healthcare systems.
Quick answers
Who was awarded contract SPE2DB26FR1PP?
SPE2DB26FR1PP was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FR1PP worth?
The government has obligated $52,458 on SPE2DB26FR1PP.
Is contract SPE2DB26FR1PP an order under another contract?
Yes. SPE2DB26FR1PP is a delivery order under SPE2DB22D2218, an indefinite delivery contract.
Was contract SPE2DB26FR1PP competed?
The extent of competition for SPE2DB26FR1PP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award